Comparative Pharmacology
Head-to-head clinical analysis: CAPLYTA versus FANAPT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPLYTA versus FANAPT.
CAPLYTA vs FANAPT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CAPLYTA (lumateperone) is a second-generation antipsychotic with a unique mechanism of action. It acts as a serotonin 5-HT2A receptor antagonist and a dopamine D2 receptor antagonist. It also functions as a serotonin transporter (SERT) inhibitor and has partial agonist activity at dopamine D1 receptors. Additionally, it modulates glutamate via effects on NMDA receptors and mTOR signaling.
FANAPT (iloperidone) is an atypical antipsychotic that exhibits high affinity for serotonin 5-HT2A and dopamine D2 receptors, with additional antagonism at alpha1-adrenergic, alpha2-adrenergic, and histamine H1 receptors. The therapeutic efficacy is primarily attributed to combined 5-HT2A and D2 receptor antagonism.
42 mg orally once daily, with or without food. Initiate at 42 mg/day; no dose titration required.
12-24 mg orally once daily, titrated from 1 mg twice daily on day 1, 2 mg twice daily on day 2, 4 mg twice daily on day 3, 6 mg twice daily on day 4, 8 mg twice daily on day 5, then 10 mg twice daily on day 6 and 7, followed by 12 mg once daily on day 8. Maximum dose: 24 mg/day.
None Documented
None Documented
The terminal elimination half-life of lumateperone is approximately 18 hours, supporting once-daily dosing with steady state achieved within 5 days.
Terminal elimination half-life is approximately 26 hours (range 22-30 hours) for the sum of parent drug and active metabolites (P95, P88, and P86); steady-state achieved within 4-5 days.
Following oral administration of lumateperone, approximately 81% of the dose is excreted in feces (mostly as metabolites) and 12% in urine (as metabolites). Less than 1% is excreted unchanged in urine.
Renal (approximately 80% as metabolites, <1% as parent drug) and fecal (approximately 20% as metabolites).
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic